Rapport Therapeutics, Inc. (RAPP) Stock Analysis
A live, multi-source view of Rapport Therapeutics, Inc. (RAPP): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 84 employees · rapportrx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Rapport Therapeutics, Inc. (RAPP) had a market capitalization of $2.20B (forward -8.8) and a beta of 1.03; the shares traded in a 52-week range of $22.06 – $52.93 (51.4% over the year).
- Market cap
- $2.20B
- Enterprise value
- $1.77B
- Forward P/E
- -8.8
- Price / book
- 5.19
- EPS (trailing)
- $-2.91
- EPS (forward)
- $-5.23
- Payout ratio
- 0.0%
- 52-week range
- $22.06 – $52.93
- 52-week change
- 51.4%
- Beta
- 1.03
- Average volume
- 356,720
- Shares outstanding
- 48.0M
- Short % of float
- 7.34%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Rapport Therapeutics, Inc. (RAPP) last closed at $43.46 (the last completed close before that scan).
Technicals at the scan: RSI 39 (neutral territory), price -9.7% versus its 20-day average, 20-day versus 50-day average spread +8.2%, MACD histogram -0.96.
Sentiment inputs: analyst consensus score 77/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RAPP; corporate insiders filed 0 buys and 14 sells (2 distinct filers, latest disclosure 2026-09-09). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Abraham Ceesay (0B/10S), Krishnaswamy Yeleswaram (0B/4S). Who is trading what
RapidTradeView pick record
RAPP has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Rapport Therapeutics, Inc. (RAPP) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RAPP.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.